{"id":5738,"date":"2024-07-10T04:00:16","date_gmt":"2024-07-10T09:00:16","guid":{"rendered":"https:\/\/nanostherapeutics.com\/?p=5738"},"modified":"2025-06-27T11:15:40","modified_gmt":"2025-06-27T16:15:40","slug":"nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting","status":"publish","type":"post","link":"https:\/\/nanostherapeutics.com\/es\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/","title":{"rendered":"Nanoscope Therapeutics se presentar\u00e1 en la reuni\u00f3n cient\u00edfica anual de la Sociedad Estadounidense de Especialistas en Retina (ASRS) de 2024"},"content":{"rendered":"
\n
\n
\n

<\/h1>\n<\/div>\n<\/div>\n<\/div>\n
\n
\n
\n
\n

DALLAS<\/span>,\u00a010 de julio de 2024<\/span>\u00a0 \u2014 Nanoscopio Therapeutics Inc.<\/a>, una empresa de biotecnolog\u00eda cl\u00ednica en fase avanzada que desarrolla terapias g\u00e9nicas para enfermedades hereditarias de la retina y degeneraciones maculares relacionadas con la edad (DMAE), anunci\u00f3 hoy que su plataforma de terapia g\u00e9nica con opsina multicaracter\u00edstica (MCO) se presentar\u00e1 en una presentaci\u00f3n del Dr. Michael Singer. en el\u00a0Reuni\u00f3n cient\u00edfica anual de la ASRS 2024<\/a>\u00a0que tendr\u00e1 lugar del 17 al 20 de julio de 2024 en el Centro de Convenciones Stockholmsm\u00e4ssan en Estocolmo, Suecia.<\/p>\n

Los detalles de la presentaci\u00f3n son los siguientes:<\/p>\n

T\u00edtulo del resumen:<\/b>\u00a0An\u00e1lisis BCVA de la terapia optogen\u00e9tica independiente de la mutaci\u00f3n MCO-010 en dosis bajas o altas para la retinitis pigmentosa: PRIMERA VEZ Resultados TOPLINE de 100 semanas de un ensayo cl\u00ednico aleatorizado controlado de forma simulada (RESTORE) de fase 2b\/3
\nTipo de sesi\u00f3n:\u00a0<\/b>Presentaci\u00f3n del simposio de \u00faltima hora
\nT\u00edtulo de la sesi\u00f3n:<\/b>\u00a0Simposio 3: Enfermedades retinianas hereditarias y gen\u00e9tica
\nFecha de la sesi\u00f3n:<\/b>\u00a0Viernes 19 de julio
\nTiempo de sesi\u00f3n:<\/b>\u00a009:17 CEST
\nPresentador:<\/b>\u00a0Dr. Michael Cantante<\/p>\n

El Dr. Singer presentar\u00e1 los datos finales del estudio RESTORE, un ensayo cl\u00ednico aleatorizado y controlado de la terapia g\u00e9nica optogen\u00e9tica MCO de Nanoscope en pacientes con p\u00e9rdida visual grave relacionada con la retinosis pigmentaria (RP). Los pacientes tratados con MCO en RESTORE experimentaron mejoras cl\u00ednicamente significativas en la agudeza visual corregida (AVCC) de forma estad\u00edsticamente significativa. El Dr. Singer analizar\u00e1 la importancia y la magnitud de la recuperaci\u00f3n visual observada en los pacientes tratados con MCO en RESTORE, en el contexto de la evoluci\u00f3n natural del deterioro visual en esta poblaci\u00f3n de pacientes.<\/p>\n

Acerca de Nanoscope Therapeutics Inc.
\n<\/b>Nanoscope Therapeutics est\u00e1 desarrollando terapias optogen\u00e9ticas gen\u00e9ticamente independientes que restauran la vista para los millones de pacientes cegados por enfermedades hereditarias de la retina, para las cuales no existe cura. El principal activo de la empresa, MCO-010,\u00a0anunci\u00f3 recientemente los datos de 100 semanas de<\/a>\u00a0el ensayo cl\u00ednico RESTORE Fase 2b\/3, multic\u00e9ntrico, aleatorizado, con doble enmascaramiento y controlado de forma simulada en los EE. UU. para la retinitis pigmentosa (NCT04945772). La compa\u00f1\u00eda tambi\u00e9n complet\u00f3 recientemente el ensayo STARLIGHT de fase 2 de la terapia MCO-010 en pacientes con enfermedad de Stargardt (NCT05417126). MCO-010 ha recibido designaciones de v\u00eda r\u00e1pida de la FDA y designaciones de medicamento hu\u00e9rfano de la FDA tanto para la retinitis pigmentosa como para la enfermedad de Stargardt. Los activos precl\u00ednicos incluyen la terapia g\u00e9nica MCO-020 administrada con l\u00e1ser no viral para atrofias geogr\u00e1ficas secundarias a la DMAE.<\/p>\n

Contacto de inversores:<\/b>
\nSocios Argot
\n212-600-1902
\nPR@nanostherapeutics.com<\/a><\/p>\n<\/div>\n<\/div>\n<\/section>\n<\/article>","protected":false},"excerpt":{"rendered":"

DALLAS,\u00a0July 10, 2024\u00a0 \u2014 Nanoscope Therapeutics Inc., a late-stage clinical biotechnology company developing gene therapies for inherited retinal diseases and age-related macular degenerations (AMD), today announced that its Multi-Characteristic Opsin (MCO) gene therapy platform will be featured in a presentation by Dr. Michael Singer at the\u00a02024 ASRS Annual Scientific Meeting\u00a0taking place from July 17-July 20, […]<\/p>\n","protected":false},"author":6,"featured_media":5740,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"footnotes":"","_links_to":"","_links_to_target":""},"categories":[13,8],"tags":[],"class_list":["post-5738","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-home-page","category-nanoscope-press-release"],"yoast_head":"\nNanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting - Nanoscope Therapeutics<\/title>\n<meta name=\"description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanostherapeutics.com\/es\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"es_MX\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting - Nanoscope Therapeutics\" \/>\n<meta property=\"og:description\" content=\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanostherapeutics.com\/es\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanoscope Therapeutics\" \/>\n<meta property=\"article:published_time\" content=\"2024-07-10T09:00:16+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-27T16:15:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"800\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Nanoscope Therapeutics\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg\" \/>\n<meta name=\"twitter:creator\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:site\" content=\"@NSTherapeutics\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Nanoscope Therapeutics\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/\"},\"author\":{\"name\":\"Nanoscope Therapeutics\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\"},\"headline\":\"Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting\",\"datePublished\":\"2024-07-10T09:00:16+00:00\",\"dateModified\":\"2025-06-27T16:15:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/\"},\"wordCount\":338,\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NSCOPE_LI_ASRS24_V2.jpg\",\"articleSection\":[\"Home Page\",\"Nanoscope Press Release\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/\",\"name\":\"Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting - Nanoscope Therapeutics\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NSCOPE_LI_ASRS24_V2.jpg\",\"datePublished\":\"2024-07-10T09:00:16+00:00\",\"dateModified\":\"2025-06-27T16:15:40+00:00\",\"description\":\"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/#primaryimage\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NSCOPE_LI_ASRS24_V2.jpg\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/NSCOPE_LI_ASRS24_V2.jpg\",\"width\":1200,\"height\":1200},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/2024\\\/07\\\/10\\\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/nanostherapeutics.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#website\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"name\":\"Nanoscope Therapeutics\",\"description\":\"Bringing Back the Light of Hope\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\"},\"alternateName\":\"Nanoscope Therapeutics\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanostherapeutics.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#organization\",\"name\":\"Nanoscope Therapeutics, Inc\",\"alternateName\":\"Nanoscope Therapeutics\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"contentUrl\":\"https:\\\/\\\/nanostherapeutics.com\\\/wp-content\\\/uploads\\\/2025\\\/03\\\/NSCOPE_Logo_Stack_2Color_512.png\",\"width\":512,\"height\":435,\"caption\":\"Nanoscope Therapeutics, Inc\"},\"image\":{\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/NSTherapeutics\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/nanoscope\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/nanostherapeutics.com\\\/#\\\/schema\\\/person\\\/5aeedc9aef0946fe8f96f98f7b1808a2\",\"name\":\"Nanoscope Therapeutics\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la Reuni\u00f3n Cient\u00edfica Anual de la Sociedad Estadounidense de Especialistas en Retina (ASRS) de 2024.","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanostherapeutics.com\/es\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/","og_locale":"es_MX","og_type":"article","og_title":"Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting - Nanoscope Therapeutics","og_description":"Our multi-characteristic opsin (MCO) platform is the first to demonstrate an ability to restore vision to retinal disease patients with severe vision loss in clincial trials. Nanoscope has developed MCO-010, the first and only broad spectrum, fast response and ultra-sensitive optogenetic technology for vision restoration that is gene-agnostic.","og_url":"https:\/\/nanostherapeutics.com\/es\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/","og_site_name":"Nanoscope Therapeutics","article_published_time":"2024-07-10T09:00:16+00:00","article_modified_time":"2025-06-27T16:15:40+00:00","og_image":[{"width":1200,"height":800,"url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_LI_BIO_Intl_2024_V2.jpg","type":"image\/jpeg"}],"author":"Nanoscope Therapeutics","twitter_card":"summary_large_image","twitter_image":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/05\/NSCOPE_ARVO_LI_2024._V2.jpg","twitter_creator":"@NSTherapeutics","twitter_site":"@NSTherapeutics","twitter_misc":{"Escrito por":"Nanoscope Therapeutics","Tiempo de lectura":"2 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/#article","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/"},"author":{"name":"Nanoscope Therapeutics","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2"},"headline":"Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting","datePublished":"2024-07-10T09:00:16+00:00","dateModified":"2025-06-27T16:15:40+00:00","mainEntityOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/"},"wordCount":338,"publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/07\/NSCOPE_LI_ASRS24_V2.jpg","articleSection":["Home Page","Nanoscope Press Release"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/","url":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/","name":"Nanoscope Therapeutics presentar\u00e1 sus novedades en la Reuni\u00f3n Cient\u00edfica Anual de la Sociedad Estadounidense de Especialistas en Retina (ASRS) de 2024.","isPartOf":{"@id":"https:\/\/nanostherapeutics.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/#primaryimage"},"image":{"@id":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/#primaryimage"},"thumbnailUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/07\/NSCOPE_LI_ASRS24_V2.jpg","datePublished":"2024-07-10T09:00:16+00:00","dateModified":"2025-06-27T16:15:40+00:00","description":"Nuestra plataforma de opsina multicaracter\u00edstica (MCO) es la primera en demostrar, en ensayos cl\u00ednicos, la capacidad de restaurar la visi\u00f3n en pacientes con enfermedades retinianas y p\u00e9rdida visual severa. Nanoscope ha desarrollado MCO-010, la primera y \u00fanica tecnolog\u00eda optogen\u00e9tica de amplio espectro, respuesta r\u00e1pida y ultrasensible para la restauraci\u00f3n de la visi\u00f3n, independiente del gen.","breadcrumb":{"@id":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/#primaryimage","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/07\/NSCOPE_LI_ASRS24_V2.jpg","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2024\/07\/NSCOPE_LI_ASRS24_V2.jpg","width":1200,"height":1200},{"@type":"BreadcrumbList","@id":"https:\/\/nanostherapeutics.com\/2024\/07\/10\/nanoscope-therapeutics-to-present-at-the-2024-american-society-of-retina-specialists-asrs-annual-scientific-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/nanostherapeutics.com\/"},{"@type":"ListItem","position":2,"name":"Nanoscope Therapeutics to Present at the 2024 American Society of Retina Specialists (ASRS) Annual Scientific Meeting"}]},{"@type":"WebSite","@id":"https:\/\/nanostherapeutics.com\/#website","url":"https:\/\/nanostherapeutics.com\/","name":"Terap\u00e9utica del nanoscopio","description":"Recuperando la luz de la esperanza","publisher":{"@id":"https:\/\/nanostherapeutics.com\/#organization"},"alternateName":"Nanoscope Therapeutics","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanostherapeutics.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Organization","@id":"https:\/\/nanostherapeutics.com\/#organization","name":"Nanoscope Therapeutics, Inc","alternateName":"Nanoscope Therapeutics","url":"https:\/\/nanostherapeutics.com\/","logo":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","contentUrl":"https:\/\/nanostherapeutics.com\/wp-content\/uploads\/2025\/03\/NSCOPE_Logo_Stack_2Color_512.png","width":512,"height":435,"caption":"Nanoscope Therapeutics, Inc"},"image":{"@id":"https:\/\/nanostherapeutics.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/NSTherapeutics","https:\/\/www.linkedin.com\/company\/nanoscope"]},{"@type":"Person","@id":"https:\/\/nanostherapeutics.com\/#\/schema\/person\/5aeedc9aef0946fe8f96f98f7b1808a2","name":"Terap\u00e9utica del nanoscopio"}]}},"_links":{"self":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5738","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/users\/6"}],"replies":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/comments?post=5738"}],"version-history":[{"count":2,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5738\/revisions"}],"predecessor-version":[{"id":9041,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/posts\/5738\/revisions\/9041"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media\/5740"}],"wp:attachment":[{"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/media?parent=5738"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/categories?post=5738"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nanostherapeutics.com\/es\/wp-json\/wp\/v2\/tags?post=5738"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}